[go: up one dir, main page]

PE20091176A1 - Nueva forma cristalina c del acido (2r)-(3-amino-2-fluoropropil)fosfinico - Google Patents

Nueva forma cristalina c del acido (2r)-(3-amino-2-fluoropropil)fosfinico

Info

Publication number
PE20091176A1
PE20091176A1 PE2008002132A PE2008002132A PE20091176A1 PE 20091176 A1 PE20091176 A1 PE 20091176A1 PE 2008002132 A PE2008002132 A PE 2008002132A PE 2008002132 A PE2008002132 A PE 2008002132A PE 20091176 A1 PE20091176 A1 PE 20091176A1
Authority
PE
Peru
Prior art keywords
fluoropropyl
amino
phosphinic acid
new crystalline
crystalline
Prior art date
Application number
PE2008002132A
Other languages
English (en)
Inventor
Ida Hoyer
Roy A Moezzifard
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20091176A1 publication Critical patent/PE20091176A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO EN FORMA CRISTALINA C DE ACIDO (2R)-(3-AMINO-2-FLUOROPROPIL)FOSFINICO CARACTERIZADO POR UN PATRON DE RAYOS X EN POLVO QUE REPRESENTA SUSTANCIALMENTE d: 5,8 ANGSTROM. REFERIDA ADEMAS A UNA FORMULACION SIENDO UTIL EN EL TRATAMIENTO DEL ASMA RELACIONADO CON EL REFLUJO, ENFERMEDADES PULMONARES, SINDROME DE DECLIVE, TRASTORNOS GASTROINTESTINAL FUNCIONAL, ENTRE OTROS
PE2008002132A 2007-12-21 2008-12-18 Nueva forma cristalina c del acido (2r)-(3-amino-2-fluoropropil)fosfinico PE20091176A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1583307P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
PE20091176A1 true PE20091176A1 (es) 2009-09-03

Family

ID=40801459

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002132A PE20091176A1 (es) 2007-12-21 2008-12-18 Nueva forma cristalina c del acido (2r)-(3-amino-2-fluoropropil)fosfinico

Country Status (5)

Country Link
AR (1) AR070046A1 (es)
PE (1) PE20091176A1 (es)
TW (1) TW200940560A (es)
UY (1) UY31555A1 (es)
WO (1) WO2009082348A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
SE0102057D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts I
WO2009014490A1 (en) * 2007-07-25 2009-01-29 Astrazeneca Ab Combination of (3-amino-2-fluoropropyl)phosphinic acid and omeprazole for treating tlesr, gerd, and nerd

Also Published As

Publication number Publication date
AR070046A1 (es) 2010-03-10
TW200940560A (en) 2009-10-01
UY31555A1 (es) 2009-08-03
WO2009082348A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
DOP2006000170A (es) Nuevos derivados de espirocromanona
JP2011518833A5 (es)
ATE465719T1 (de) Oral zerfallende zusammensetzung von olanzapin oder donepezil
JP2014515038A5 (es)
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
DK2150530T3 (da) Substituerede sulfonamid-derivater
CY1109369T1 (el) Υποκατεστημενες πυρρολοπυριδινες, οι ενωσεις που τις περιεχουν, η διαδικασια παρασκευης τους και η χρηση τους
PE20070828A1 (es) Composicion farmaceutica que contiene una sal de glicopirronio
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
PE20121467A1 (es) Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica
MX2010002407A (es) Cocristales y composiciones farmaceuticas que los comprenden.
JP2015509075A5 (es)
CY1113279T1 (el) Φαρμακευτικη συνθεση 271
JP2011515406A5 (es)
ECSP088374A (es) Formulacion de aerosol para inhalacion
PE20091176A1 (es) Nueva forma cristalina c del acido (2r)-(3-amino-2-fluoropropil)fosfinico
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
PE20141411A1 (es) Nueva forma de cristal
AR069649A1 (es) 4-(2,3- difluoro-6-(2- fluoro-4- metil- fenilsulfanil)- fenil)- piperidina
PE20090639A1 (es) Formas polimorficas de (s)-2-((4-benzofuranil)carbonilaminometil)-1-((4-(2-metil-5-(4-fluorofenil))tiazolil)carbonil)piperidina
EA201001095A1 (ru) Соединение (r)-n*6*-этил-6,7-дигидро-5н-индено[5,6-d]тиазол-2,6-диамин и его применение в качестве антипсихотического средства
UY31558A1 (es) Nueva forma cristalina del acido (2r)-(3-amino-2-fluoropropil) fosfinico
EA201490757A1 (ru) 5,5-диметил-2-пропил-гексагидро-2,4а-метанонафталин-1-он в качестве ароматизирующего вещества

Legal Events

Date Code Title Description
FD Application declared void or lapsed